USFDA completes inspection at Laurus Labs’ Visakhapatnam facility

09 Nov 2019 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Laurus Labs’ FDF & API Integrated Facility, Unit 2, at Visakhapatnam. The inspection was carried out from November 04 - 08, 2019.

The company has been issued with two observations which are procedural in nature. This is a product pre-approval audit by USFDA.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

605.95 19.15 (3.26%)
19-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1733.45
Dr. Reddys Lab 1171.90
Cipla 1498.50
Lupin 2060.70
Zydus Lifesciences 909.60
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...